Bristol-Myers Squibb Co (NYSE: BMY) is a biopharmaceutical company that discovers, develops, manufactures, markets, and sells medicines for serious diseases. Revenue comes from prescription drug sales across oncology, hematology, immunology, cardiovascular, and neuroscience therapeutic areas. The company was incorporated in Delaware in August 1933 as Bristol-Myers Company, successor to a New York business started in 1887, and adopted its current name in 1989 following a merger. BMY operates as a single business segment, combining the scale of a large pharmaceutical company with a focus on biologic and small-molecule drug innovation. The company holds product exclusivity through patents and intellectual property on its marketed medicines, which is the primary structural protection for its revenue streams. BMS licenses, manufactures, and distributes its products globally, with foreign operations representing a material portion of the business as disclosed in its FY2025 10-K filed February 11, 2026.

Revenue model

Transactional prescription drug sales. Revenue is generated when medicines are sold to distributors, wholesalers, hospitals, and pharmacy benefit managers. Licensing and alliance arrangements provide additional revenue streams.

Products and services

Medicines across oncology, hematology, immunology, cardiovascular, and neuroscience therapeutic areas. Specific brand names are listed in the Exhibit Index of the FY2025 10-K (accession 000001427226000004); individual brand-level revenue figures are not extractable from the provided excerpts.

Customers and end markets

End markets include patients with serious diseases in oncology, hematology, immunology, cardiovascular, and neuroscience. Distribution channels include wholesalers, hospitals, and pharmacy benefit managers as disclosed in the FY2025 10-K.

Value-chain role

Vertically integrated biopharmaceutical company spanning drug discovery, development, clinical trials, manufacturing, marketing, and distribution.

Geographic exposure

Operates in the United States and internationally. Foreign operations are identified as a material component of the business in the FY2025 10-K; specific regional revenue breakdowns are not available in the provided excerpts.

Source: SEC 10-K, filed 2026-02-11

Industry: Pharmaceutical Preparations Peers: Catalent, Inc. Eli Lilly and Co Johnson & Johnson Merck & Co Inc Organon & Co Pfizer Inc Royalty Pharma PLC Viatris Inc Zoetis Inc